Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Study:

A Phase I/II Trial of Temozolomide and ABT-888 in Subjects With Newly Diagnosed Glioblastoma Multiforme

Rationale:

ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with radiation therapy and temozolomide may kill more tumor cells.

Purpose:

This phase I/II trial is studying the side effects and best dose of ABT-888 when given together with radiation therapy and temozolomide and to see how well it works in treating patients with newly diagnosed glioblastoma multiforme.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: temozolomide
Drug: veliparib
Genetic: DNA methylation analysis
Genetic: gene expression analysis
Genetic: mutation analysis
Genetic: proteomic profiling
Other: high performance liquid chromatography
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Other: mass spectrometry
Other: pharmacogenomic studies
Other: pharmacological study
Procedure: adjuvant therapy
Radiation: radiation therapy
Phase 1/Phase 2

Verified by Sidney Kimmel Comprehensive Cancer Center May, 2012

Sponsored by: Sidney Kimmel Comprehensive Cancer Center
Information provided by: Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00770471

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Larry Kleinberg, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site